IPM Take
GIST is already a precision oncology disease, but it is not a solved disease. KIT inhibition changed outcomes two decades ago. Resistance then became the next wall. Velzatinib matters because the field is now asking whether a broader KIT inhibitor can control clinically relevant mutations earlier and more effectively. The access issue is specialist interpretation: mutation biology must guide sequencing, not sit buried in a report.
Executive Summary
At ASCO 2026, velzatinib, formerly IDRX-42, was presented in advanced gastrointestinal stromal tumours through StrateGIST 1 analyses. GSK’s ASCO/EHA 2026 release stated that first results in first-line advanced GIST showed promising activity and tolerability across KIT mutations and that the data had accelerated initiation of a Phase III frontline trial. ASCO abstract #11501 evaluated velzatinib as first- or second-line therapy by KIT mutation status, while abstract #11520 reported efficacy and circulating tumour DNA response data from StrateGIST 1.
Why it matters
- Clinicians: Need to place new KIT inhibitors correctly across first-line, second-line and resistant GIST pathways.
- Diagnostics / pathology: KIT mutation status and ctDNA response may become more important for treatment selection and monitoring.
- Patients / advocates: Rare cancer access depends on referral to centres that understand mutation-driven sequencing.
GIST is often presented as a success story for targeted therapy. That is fair, but incomplete. Imatinib changed the field, yet resistance continues to shape the lives of patients with advanced disease.
The ASCO 2026 velzatinib data speak directly to that problem. The drug is being developed as a selective KIT inhibitor with activity across clinically meaningful KIT variants. That matters because resistance in GIST is not random. It is often mutation-driven, and different mutations can affect which drug is likely to work.
The early data are encouraging, but still early. This is not yet a routine-care conclusion. The more useful signal is strategic: GIST treatment may be entering a phase where sequencing depends more tightly on mutation profile and possibly ctDNA dynamics.
For IPM, this rare cancer story is a reminder that precision oncology does not end with the first targeted therapy. It has to follow resistance, adapt to tumour evolution and make specialist expertise available before patients exhaust their options.
